Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.43 |
| ▸ | MAOB | P27338 | 11/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | CASP1 | P29466 | 1/20 | 0.40 |
| ▸ | CASP7 | P55210 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 9/20 | 0.39 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6219966 | 0.93 | MAOB (0.48) | HRH3MAOBPTGS2MAOAHSD17B1 | |
| SCHEMBL3965663 | 0.83 | PTGS2 (0.51) | HRH3MAOBPTGS2CASP1CASP7 | |
| SCHEMBL11732154 | 0.76 | MAOA (0.52) | HRH3MAOBMAOAHSD17B1 | |
| SCHEMBL9223479 | 0.76 | MAOA (0.52) | HRH3MAOBMAOAHSD17B1 | |
| SCHEMBL11741286 | 0.74 | MAOA (0.54) | HRH3MAOBMAOAHSD17B1 | |
| SCHEMBL4813615 | 0.73 | MAPK14 (0.52) | HRH3MAOBPTGS2CASP1CASP7 | |
| SCHEMBL4403542 | 0.71 | CASP1 (0.44) | HRH3MAOBPTGS2CASP1CASP7 | |
| SCHEMBL8597524 | 0.71 | HRH3 (0.49) | HRH3MAOBPTGS2MAOA | |
| SCHEMBL1339241 | 0.70 | MAOB (0.44) | HRH3MAOBPTGS2CASP1CASP7 | |
| SCHEMBL5384562 | 0.69 | BTK (0.39) | HRH3MAOBPTGS2HSD17B10MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7320986-B2 | Fused tri and tetra-cyclic pyrazole kinase inhibitors | ABBOTT LABORTORIES (US) | 2008-01-22 | — | — | US | disclosed |
| US-20040259904-A1 | Fused tri and tetra-cyclic pyrazole kinase inhibitors | ABBVIE INC. | 2004-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259904-A1 | Fused tri and tetra-cyclic pyrazole kinase inhibitors | TK1, MAP3K19, MAP3K20 | HRH3 2806/4885MAOB 3311/4885PTGS2 2198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.